A case of a 19-year-old man with ulcerative colitis (UC) developed multiple pulmonary nodular shadows with cavity formation, elevated perinuclear antinuclear cytoplasmic antibody (PANCA)and positive lymphocyte stimulation test by drug (DLST) for mesalazine suggesting mesalazine induced Wegener's granulomatosis (WG). Transbronchial biopsy specimens were consistent with WG and thoracoscopic biopsy specimens were consistent with bronchiolitis obliterans organizing pneumonitis (BOOP). Wediagnosed WGwith BOOP-like variant, which was induced by mesalazine. To our knowledge, this is the first report of a limited form of WGassociated with orally administered mesalazine.
On July ll, 2001, a 19-year-old man presented with a 7-day history of low grade fever. He was referred by a local doctor for further examination of abnormal shadow on chest imaging study. The patient had a 9-month history of ulcerative colitis (UC) and had taken mesalazine (Pentasa®), 2.25 g po tid since December 2000. Intermittent bloody diarrhea had exacerbated in February 2001 and 20 mg of prednisolone for one month was necessary to establish control. Thereafter, intermittent bloody diarrhea was improved and mesalazine alone was administrated from March 2001. The patient had no known drug allergies. He was a preparatory school student, and did not smoke.
On examination, the patient was a thin man with a blood pressure of 122/68 mmHg,pulse 80/min, respiratory rate 14/ min, and temperature 37. 1°C.
On admission, white blood cell count was 8,300/mm3. Serum C-reactive protein was elevated (3. 1 mg/dl). Serum perinuclear antinuclear cytoplasmic antibody (ANCA) by ELISA, PANCA(Anti-myeloperioxidase ANCA, SRL-INC. co, Japan) was slightly increased to 20 EU and CANCA(Anti-proteinase-3 ANCA,SRL-INC. co, Japan) was normal value. The lymphocyte stimulation test by drug (DLST) for mesalazine was positive (stimulation index 1 84%). Urinalysis was negative for protein, occult blood, sugar, cells and casts. Stool was negative for occult blood. Routine bacteriological, fungal, and mycobacterial cultures of sputumwere negative. Plain chest radiograph and CTscanning revealed two tumors with cavity formation in bilateral B6 and a nodular shadow in right B4 ( (Fig. IB) . These findings were compatible with Wegener's granulomatosis (WG). Resection of the right B4 nodule by thoracoscope was undertaken for the diagnosis. The thoracoscopic biopsy specimen showed typical polypoid granuloma formed from respiratory bronchiole to alveoli and the matrix contained variable numbers of lymphocytes, macrophages and eosinophils (Fig. 1C) . These specimens were compatible with bronchiolitis obliterans organizing pneumonitis (BOOP). As we diagnosed a limited form ofWGwith BOOPlike variant, he was treated by adding prednisolone of 20 mg to mesalazine. Staining for acid-fast bacilli and fungi were negative in both the transbronchial and thoracoscopic specimens. After one month with prednisolone and mesalazine a chest radiograph showed no pulmonary lesions and serum PANCA was slightly decreased to 13 EU. Prednisolone was gradually tapered and discontinued in November 2001. However, one month later, the high grade fever of 38°C recurred and a plain chest radiograph revealed right lower infiltration. He was treated only with 20 mgof prednisolone, as we consid- ered that mesalazine induced the lung lesion. Twoweeks later, he had no complaints and the chest radiograph was improved.
Discussion
Pulmonary manifestations of UCare very rare, although a constellation of extraintestinal manifestations affecting various organs or organ systemshas been described in association with IBD ( 1 ). Turner-Warwick pointed to the possible association of UCand respiratory disease (2), and Kraft et al reported that respiratory involvement was included on the list of established complications of IBD (3) . Following these reports, several publications described similarly disabling bronchitis or bronchiectasis in patients with IBD. Later on, panbronchiolitis, BOOPand interstitial pneumonitis mimicking WGwere reported in patients with inflammatory bowel disease (IBD).
Camus et al (1) reported two patients with UCmimicking a limited form of WG.They both had inactive UC, fever and positive PANCA.Stebbing et al also reported a case of UC mimicking a limited form of WG(4). All of these cases had positive immunofluorescence tests for PANCA.In our case, serum PANCAwas also slightly increased. Up to 90% of patients with WGwith active disease are ANCApositive. Although the majority are CANCApositive by immunofluorescence, a significant minority (10%) are PANCApositive. A substantial proportion of patients with IBD, particularly those with UC, also have ANCA.As with systemic vasculitis, the precise role ofANCAin the pathogenesis of IBD remains unclear.
Sulfasalazine (Salazopyrin) is widely used in the treatment of UC, although a high incidence of side effects has been reported. Jones and Malonereported a case of lung disease attributable to sulfasalazine hypersensitivity that resembles simple pulmonary eosinophilia (5). Salerno et al reported a patient with UC who developed pulmonary symptoms, peripheral nodular lung infiltrates, and an elevated CANCAsuggesting WG(6). Sulfasalazine and 5-aminosalicylic acid are also known as mesalamine or mesalazine, which has been thought to be free of most side effects. However, even in mesalazine, bronchiolitis and interstitial infiltrates were reported. In these previous reports of sulfasalazine or mesalazine-induced lung disease, DLSTwas not performed except in one report (7) . In this case, as the DLSTfor mesalazine was positive, we considered the possibility of mesalazine-induced lung disease. However, we continued the use of mesalazine since deterioration of UC was a major concern, and 20 mgof prednisolone was added.
Because the lung disease recurred, we should have stopped masalazine in the first episode and treated only with prednisolone.
The transbronchial biopsy specimen was thought to be consistent with WG,while the thoracoscopic biopsy specimen was thought to be consistent with BOOPor eosinophilic pneumonia. Uner et al (8) reported that the major pathologic findings in WGresembled BOOPand constituted a BOOP-like variant (9) . Therefore, we diagnosed this patient as having a limited form ofWGin UC. To our knowledge, this is the first report of a limited form of WGwith BOOP-like variant that might be associated with orally administered mesalazine. Weconclude that adverse pulmonary reactions to mesalazine must be considered in the differential diagnosis of pulmonary involvement such as a limited form ofWGin patients with UC receiving mesalazine therapy.
